Accessibility to biologics and its impact on disease activity and quality of life in patients with rheumatoid arthritis in Kuwait

Adeeba Al-Herz, Khuloud Saleh, Adel Al-Awadhi, Waleed Al-Kandari, Eman Hasan, Aqeel Ghanem, Mohammed Hussain, Yaser Ali, Ebrahim Nahar, Ahmad Alenizi, Sawsan Hayat, Fatemah Abutiban, Ali Aldei, Hebah Alhajeri, Naser Alhadhood, Husain Bahbahani, Hoda Tarakmeh, Khaled Mokaddem, Ahmad Khadrawy, Ammad FazalAgaz Zaman, Ghada Mazloum, Youssef Bartella, Sally Hamed, Ramia Alsouk, Ahmed Al-Saber

Research output: Contribution to journalArticle

2 Downloads (Pure)


Objective: Biologics are indicated in rheumatoid arthritis (RA) in case of persistent high disease activity despite conventional disease-modifying anti-rheumatic drugs (cDMARDs) or patients with contraindications to cDMARDs or poor prognostic factors. The purpose of this study was to compare the prescription rates of biologics in Kuwaiti and non-Kuwaiti patients and to assess whether this had an impact on disease activity and quality of life in RA patients. Methods: Data were extracted from the Kuwait Registry for Rheumatic Diseases. Adult patients who satisfied the ACR classi- fication criteria for RA from four major hospitals in Kuwait were evaluated from February 2013 through May 2018. The treatment agents, disease activity, and quality of life of Kuwaiti patients were compared with non-Kuwaiti patients. Results: A total of 1651 RA patients were included; 806 (48.8%) were Kuwaiti patients. Among Kuwaiti patients, 62.5% were on biologic drugs in comparison with 14% of non-Kuwaiti patients. In comparison with non-Kuwaiti patients, Kuwaiti patients had significantly lower numbers of swollen joints (p < 0.001) and disease activity score-28 scores (p = 0.02) and less steroid use (p < 0.001) yet a significantly higher health assessment questionnaire-disability index (p < 0.001). Regression analysis showed that DAS-28 scores were significantly associated with the treatment type (p < 0.001) and that nationality was significantly predictive of the treatment type (p < 0.001). Conclusion: In the setting of easy accessibility to treatment for Kuwaiti patients, biologics were prescribed by rheumatologists at a higher rate than for non-Kuwaitis. This may explain the lower disease activity and the lower rate of steroid use in Kuwaiti patients than non-Kuwaitis.
Original languageEnglish
Number of pages7
JournalClinical Rheumatology
Publication statusPublished - 12 Oct 2020


  • biologics
  • DAS-28
  • Kuwait
  • rheumatoid arthritis

Cite this

Al-Herz, A., Saleh, K., Al-Awadhi, A., Al-Kandari, W., Hasan, E., Ghanem, A., Hussain, M., Ali, Y., Nahar, E., Alenizi, A., Hayat, S., Abutiban, F., Aldei, A., Alhajeri, H., Alhadhood, N., Bahbahani, H., Tarakmeh, H., Mokaddem, K., Khadrawy, A., ... Al-Saber, A. (2020). Accessibility to biologics and its impact on disease activity and quality of life in patients with rheumatoid arthritis in Kuwait. Clinical Rheumatology.